
|Articles|August 1, 2003
Multiple-dose regimen safe for neovascular AMD
Author(s)Cheryl Guttman
Fort Lauderdale, FL-In a phase I, multicenter, randomized trial, the anti-VEGF antibody fragment rhuFab V2 was shown to be safe and well-tolerated in eyes with neovascular age-related macular degeneration (AMD), according to Philip J. Rosenfeld, MD, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
2
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
3
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
4
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
5















































.png)


